Navigation Links
A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients

e specifically, the mean HbA1c level among treated patients was reduced 0.43%, 0.94% (p<0.05), 1.09% (p<0.05), 1.12% (p<0.05), 1.21% (p<0.05), and 1.14% in months 1, 2, 3, 4, 5, and 6 post-treatment, respectively. In contrast, the mean HbA1c levels of the placebo group ranged from a reduction of 0.1% to an increase of 1.0% over the same period. In addition to the HbA1c reductions, the data demonstrated decreases in fasting blood glucose levels as well as improvements in glucose tolerance over a six month period following treatment with E1-I.N.T.(TM). Trends in increased insulin levels as measured with an oral glucose tolerance test were also observed, particularly in patients where the HbA1c levels decreased over 1% with E1-I.N.T.(TM) therapy. These data are consistent with the increased glucose control observed in diabetes animal models where a short treatment with E1-I.N.T.(TM) resulted in a sustained increase in beta cell mass and function. These clinical improvements, including HbA1c reductions greater than 1% in patients six month post-treatment, highlight the potential that E1-I.N.T.(TM) therapy could provide patients significant clinical benefit in excess of 6 months.

Safety and Tolerability Findings:

There were no serious adverse events noted during the study. As described in Transition's press release of March 5th, 2007, the most common adverse events reported by patients receiving E1-I.N.T.(TM), were nausea, diarrhea, headaches and vomiting which were generally mild to moderate in nature. The majority of these adverse events were reported during the treatment period with the occurrence of adverse events in the post-treatment phase being similar in both the treated and placebo groups.

Next Steps:

In this study, the tolerable dosing levels of E1-I.N.T.(TM) and the efficacy parameters to be employed in future clinical studies were established. Building upon these sustained efficacy findings, the next steps in clinical development w
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
5. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
6. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
7. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
8. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
9. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
10. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
11. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
Post Your Comments:
(Date:7/30/2015)... 30, 2015 Future Market Insights ... "Continuous Glucose Monitoring Systems Market: Global Industry Analysis and ... the global continuous glucose monitoring systems market was valued ... to reach US$ 788.4 Mn by 2020, registering a ... 2020. Global continuous glucose monitoring systems market ...
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, Inc. ... second Phase III clinical study for Ozenoxacin, a ... Medimetriks owns the exclusive U.S. rights to Ozenoxacin ... conducted at 44 centers with an emphasis on ... aged 2 months and older with a clinical ...
(Date:7/30/2015)... July 30, 2015   Gaumard® Scientific Company ... UNI®, the world,s first operating system to support ... available exclusively to Gaumard users. UNI® version 2.27.21.0 ... Newborn Tory™ S2200, as well as improvements to ... clinical measures such as EtCO 2 .  ...
Breaking Medicine Technology:Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 2Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 3
... WASHINGTON, Sept. 29, 2011 As small businesses struggle ... indicates concern that forthcoming Essential Health Benefits regulations ... drug companies to raise prescription drug costs, the ... benefit managers (PBMs) administer drug benefits for thousands of ...
... 29, 2011 A drug recently approved by the U.S. ... targets a malfunctioning gene discovered more than a decade earlier ... scientific findings from St. Jude can be translated into therapies ... adults. The drug is Xalkori (crizotinib). The FDA ...
Cached Medicine Technology:Some Essential Benefits Rules Could Worry Small Businesses 2St. Jude Children's Research Hospital Discovery Aided Quest for Adult Cancer Drug 2St. Jude Children's Research Hospital Discovery Aided Quest for Adult Cancer Drug 3
(Date:7/31/2015)... ... July 31, 2015 , ... Precision Aesthetics is New York’s ... It was also the first provider of Exilis non-surgical fat reduction in New York. ... it has attracted a large International clientele. Many patients travel to New York ...
(Date:7/31/2015)... ... 31, 2015 , ... Last week, the Mesothelioma Applied Research ... be accessed by visiting http://www.curemeso.org/store . , “Our new store features a ... whenever a product is purchased, the Meso Foundation receives a $5.00 donation,” said ...
(Date:7/31/2015)... ... 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival of ... Aesthetics released this new applicator in the United States as an upgrade to the ... The original applicator required a 2 hour treatment time. The new CoolSmooth ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... workshop at its new True North Conference Center. The medical community, social workers, ... Jacksonville community may be more aligned in the effort to better understand and ...
(Date:7/31/2015)... ... July 31, 2015 , ... Coco Libre announced today that their flagship Organic ... the 2015 Vans US Open of Surfing, July 25 through August 2 in Huntington ... sugar” on the market, is a natural choice given the Open’s commitment to sustainable ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2
... known that pregnant women who develop pre-eclampsia, which are a ... the risk of having a stroke during pregnancy. // ... Centres for Disease Control and Prevention now report that pre-eclampsia ... ,Dr David W. Brown and colleagues in Atlanta used ...
... rejected the UN findings that claim an extra 4,000 cancer ... Chernobyl disaster,// which struck 20 years ago. Instead, the group ... 93,000. ,Most of these victims would ... in April 1986 was one of the worst nuclear accidents ...
... Generally Vitamin D is found in either sunrays or in ... for that. // The research says that brief UV exposure ... D. The Food and Drug Administration proposed study is being ... to the concern with the vitamin deficiency. It would be ...
... died and up to 25,000 affected in a malaria epidemic in ... fanned out to take preventive steps and cure those hit by ... ,The minister said 50 people had died of cerebral malaria since ... Golaghat being the worst hit. ,"We have been able ...
... April issue of Archives of Dermatology, almost 50% of high ... their newspapers. // Tanning advertisements have been found in newspapers ... were about 40 tanning advertisements, 15 of whom did speak ... months. ,The article carries related information about the ...
... the lifestyle and socioeconomic status of 422 students with reference ... who lack sleep tend to be overweight //. ... Laval's faculty of medicine and was based on a telephonic ... children’s body mass index revealed that 24% of the girls ...
Cached Medicine News:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: